ORGS vs. APM, NRSN, NRBO, INDP, VINC, NERV, VBIV, FLGC, GLTO, and AYTU
Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Aptorum Group (APM), NeuroSense Therapeutics (NRSN), NeuroBo Pharmaceuticals (NRBO), Indaptus Therapeutics (INDP), Vincerx Pharma (VINC), Minerva Neurosciences (NERV), VBI Vaccines (VBIV), Flora Growth (FLGC), Galecto (GLTO), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.
22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 64.0% of Aptorum Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Aptorum Group received 40 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 68.33% of users gave Aptorum Group an outperform vote.
In the previous week, Aptorum Group had 1 more articles in the media than Orgenesis. MarketBeat recorded 3 mentions for Aptorum Group and 2 mentions for Orgenesis. Orgenesis' average media sentiment score of 1.43 beat Aptorum Group's score of 1.19 indicating that Orgenesis is being referred to more favorably in the media.
Aptorum Group has a net margin of 0.00% compared to Orgenesis' net margin of -1,010.50%. Aptorum Group's return on equity of 0.00% beat Orgenesis' return on equity.
Orgenesis has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Aptorum Group has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
Aptorum Group has lower revenue, but higher earnings than Orgenesis.
Summary
Aptorum Group beats Orgenesis on 8 of the 13 factors compared between the two stocks.
Get Orgenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orgenesis Competitors List
Related Companies and Tools
